Intellia Therapeutics reports FDA has accepted its biologics license application for Lonvoguran Ziclumeran (Lonvo-Z) with priority review for hereditary angioedema.

Observed price moves

• NTLA+5.96%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.